CDAK Codiak BioSciences Inc.

18
+0.19  (+1%)
Previous Close 17.81
Open 17.73
52 Week Low 7.9
52 Week High 37.85
Market Cap $396,789,894
Shares 22,043,883
Float 12,751,146
Enterprise Value $314,343,175
Volume 26,096
Av. Daily Volume 125,760
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
exoSTING
Solid tumors
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
exoIL-12
Cutaneous T cell lymphoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021. Details are as follows:

    William Blair Biotech Focus Conference 2021
    Date: Wednesday, July 14
    Panel: Developing Therapies for the Next Immuno-Oncology Targets
    Time: 2:10-3:10 p.m.

    Date: Thursday, July 15
    Panel: Non-Viral Drug Delivery
    Time: 2:00-2:45 p.m.

    Live webcasts of the virtual panel discussions…

    CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021. Details are as follows:

    William Blair Biotech Focus Conference 2021

    Date: Wednesday, July 14

    Panel: Developing Therapies for the Next Immuno-Oncology Targets

    Time: 2:10-3:10 p.m.

    Date: Thursday, July 15

    Panel: Non-Viral Drug Delivery

    Time: 2:00-2:45 p.m.

    Live webcasts of the virtual panel discussions will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. Archived replays will be available for approximately 30 days following the events.   

    About Codiak BioSciences

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.



    Investor Contact:
    Christopher Taylor
    VP, Investor Relations and Corporate Communications
    T: 617-949-4220
    E: 
    
    Media Contact:
    Lindy Devereux
    Scient PR
    T: 646-515-5730
    E: 

    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak's Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company's lead programs, exoSTING™ and exoIL-12™.   

    "Benny has been an ardent champion…

    CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak's Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company's lead programs, exoSTING™ and exoIL-12™.   

    "Benny has been an ardent champion of the potential of exosome-based therapeutics since he joined Codiak in 2016 and has skillfully led our clinical development efforts as we have endeavored to break new ground with a novel modality," said Douglas E. Williams, Ph.D., CEO, Codiak. "We are extremely grateful for Benny's many contributions to Codiak, and we are glad that he will remain involved with the company. We wish him every success as he takes the helm of a start-up hemostasis and thrombosis company, which is an ideal fit with Benny's background and expertise. Benny has built a talented team at Codiak and the addition of Jennifer Wheler, M.D. as Chief Medical Officer in recent months has positioned the company well as we work to advance our novel programs and further expand our clinical pipeline."

    Most recently, Dr. Sorensen has held the role of Senior Vice President, Strategic Projects at Codiak and before that, SVP, Head of Clinical Development. Dr. Sorensen was instrumental in the design and initiation of Codiak's first two clinical programs – exoIL-12 and exoSTING – which were the first ever engineered exosome-based therapeutic candidates to enter the clinic. Preliminary topline data for the ongoing Phase 1/2 trial of exoSTING are expected in Q3 of this year and initial data from the exoIL-12 Phase 1 program in cutaneous T cell lymphoma patients are anticipated by year end.

    Dr. Sorensen stated, "I am honored to be joining Codiak's Scientific Advisory Board, and to serve along with some of the world's thought leaders in oncology and immunology. I believe strongly in the potential of Codiak's science and its engEx™ Platform that's been built and eagerly await our first patient data sets in trials for exoSTING and exoIL-12, expected later this year. I look forward to continuing to work closely with the company in my new advisory roles."

    About Codiak BioSciences

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of the Company's engEx Platform, engEx product candidates and engineered exosomes generally, including future development plans, data releases and timing with respect thereto. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Codiak's Annual Report on Form 10-K for the year ended December 31, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak's subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.



    Investor Contact:
    Christopher Taylor
    VP, Investor Relations and Corporate Communications
    T: 617-949-4220
    E: 
    
    Media Contact:
    Lindy Devereux
    Scient PR
    T: 646-515-5730
    E: 

    Primary Logo

    View Full Article Hide Full Article
  3. New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity…

    New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity to Tessera's Board of Directors," said Geoffrey von Maltzahn, Ph.D., CEO and Co-Founder of Tessera. "Elliott has overseen more than a dozen new medications on their way to market, and Mary has guided major strategic, fundraising, and partnership efforts. Together, they offer decades of experience that will help us rapidly grow Tessera and to fulfill our mission of curing diseases by writing in the code of life."

    "The next frontier in medicine will be therapeutics that cure and provide enduring protection against disease. I am excited to welcome Elliott and Mary to the team at Tessera and look forward to working closely with them as we advance Tessera's Gene Writing platform and pioneer the future of genetic medicine," said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board, Tessera and CEO of Flagship Pioneering.

    Dr. Sigal brings decades of clinical experience in drug discovery, drug development, and corporate strategy to Tessera's Board of Directors. He currently serves as a senior advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for Adaptimmune Therapeutics, Surface Oncology, Vir Therapeutics, and Affinia. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. He previously served on the Board of Directors for the gene therapy company, Spark Therapeutics. Dr. Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as the company's Chief Scientific Officer and President of R&D from 2004 until 2013. Under his leadership, fourteen new medicines came to market in multiple therapeutic areas including virology, oncology, immunology, psychiatry, metabolic diseases and cardiovascular disease. During his tenure, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal received his M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school, he received his B.S., M.S., and Ph.D. in Industrial Engineering from Purdue University.

    "Tessera's Gene Writing technology represents a major breakthrough in the field with potential to fundamentally change the future of medicine across many therapeutic areas," said Dr. Elliott Sigal. "I am honored to join the Board and look forward to helping guide the company through continued growth and innovation."

    Dr. Rozenman brings more than 15 years of scientific expertise, company building, and transactions leadership in the biotech industry to Tessera's Board of Directors. She serves as the CFO and CBO of insitro, leading strategic and operational finance and accounting strategy, business development, investor relations, corporate communications, as well as project and portfolio management. Prior to insitro, Dr. Rozenman served as the Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she oversaw business development and partnerships with companies including Regeneron/Sanofi and Nestle Health Science and supported the company's strategic finance and investor relations efforts. Across her time at both insitro and Aimmune, Dr. Rozenman has raised more than $1 billion in capital through a range of public and private transactions, including leadership of Aimmune's IPO in 2015. She received her Ph.D. in Organic Chemistry and Chemical Biology from Harvard University and her B.A. in Biochemistry and Russian Literature from Columbia University.

    "Tessera is pioneering Gene Writing at a pivotal moment for drug discovery, as we rapidly expand our understanding of the genetic drivers of disease. Tessera's work to write into the genome may open opportunities to cure and prevent a broad range of diseases. I am thrilled to join the Board during such an exciting time in the company's growth and look forward to partnering with Geoff and the world class Tessera team," said Dr. Mary Rozenman.

    For more information on Tessera, including how Gene Writing works, partnership opportunities, and job openings, visit www.tesseratherapeutics.com.

    About Tessera Therapeutics

    Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ:AXLA), Codiak BioSciences (NASDAQ:CDAK) Denali Therapeutics (NASDAQ:DNLI), Evelo Biosciences (NASDAQ:EVLO), Foghorn Therapeutics (NASDAQ:FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

    View Full Article Hide Full Article
  4. – Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer –

    – Konstantin Konstantinov, Ph.D. named Chief Technology Officer –

    CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak's preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has spearheaded the company's manufacturing and process sciences since Codiak's inception, has been named Chief Technology Officer.

    "Both Sriram and Konstantin…

    – Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer –

    – Konstantin Konstantinov, Ph.D. named Chief Technology Officer –

    CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak's preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has spearheaded the company's manufacturing and process sciences since Codiak's inception, has been named Chief Technology Officer.

    "Both Sriram and Konstantin are highly-regarded experts in their respective fields and have been instrumental in the realization of our exosome engineering platform and our significant progress as a company to date," said Douglas E. Williams, Ph.D., CEO, Codiak. "As the architect of our lead R&D programs, Sriram is currently driving the research innovation critical to cultivating the next generation of our pipeline. With his background in oncology and immuno-oncology, he has skillfully guided two of our exosome therapeutic candidates to the clinic and a third toward IND. Konstantin's work to build – from the ground up – a robust and reproducible exosome manufacturing process capable of producing scalable, GMP-grade therapeutics forms the backbone of our entire engEx™ platform and is setting new standards for our industry. I am delighted to work alongside these long-time colleagues as we chart the path for Codiak's next phase of growth."

    Prior to this appointment, Dr. Sathyanarayanan was Senior Vice President, Preclinical Development. In this role, he designed and led the preclinical evaluation of all of Codiak's development programs in oncology/immuno-oncology, including exoIL-12™ and exoSTING™, which are currently in Phase 1/2 clinical trials, and exoASO™-STAT6, for which Codiak expects to file an Investigational New Drug application this year. Dr. Sathyanarayanan joined Codiak in 2017 as Vice President, Biology and Translational Sciences after spending four years developing biomarker strategies to enable clinical development of novel cancer immunotherapy agents, including JTX-2011 from inception to Phase 2 clinical development, at Jounce Therapeutics as Senior Director, Translational Sciences. He began his career in drug discovery at Merck Research Laboratories where he was responsible for building translational oncology strategy for multiple biologics and small molecules programs including Dalotuzumab and Ridaforolimus. Dr. Sathyanarayanan completed his post-doctoral research at the University of Pennsylvania School of Medicine. He received his Ph.D. in microbiology and cell biology from the Indian Institute of Science and masters and undergraduate degrees in biochemistry from PSG College.

    Dr. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences. Before joining Codiak in January 2016, he was responsible for the late-stage bioprocess and technology development at Sanofi's Boston hub, including all functions from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer-reviewed papers and has more than 15 patents and patent applications. Over the course of his career, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he forged the development of an end-to-end integrated continuous biomanufacturing platform, which led the way for a strategic technological shift in the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in biochemical engineering from Osaka University in Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware. Dr. Konstantinov is the recipient of many awards for his contributions to the field, including most recently the American Chemical Society and AIChE's D.I.C. Wang Award for Excellence in Biochemical Engineering.

    About Codiak BioSciences

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of the Company's engEx Platform, engEx product candidates and engineered exosomes generally, including future development plans, regulatory filings, data releases and timing with respect thereto. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Codiak's Annual Report on Form 10-K for the year ended December 31, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak's subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.



    Investor Contact:
    Christopher Taylor
    VP, Investor Relations and Corporate Communications
    T: 617-949-4220
    E: 
    
    Media Contact:
    Lindy Devereux
    Scient PR
    T: 646-515-5730
    E: 

    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    "At Flagship Pioneering, we are re-imagining how to prevent and treat disease, feed a growing population, and sustain our planet. We do this by harnessing chemistry, biology, and machine learning/AI to build cohesive, integrated platforms, each with the potential for multiple transformative products," said Noubar Afeyan, Ph.D., Founder and Chief Executive Officer of Flagship Pioneering. "There is no better example of the power of bioplatform companies than Flagship-founded Moderna, which was able to rapidly shift its focus in 2020 to develop, test, and deploy its COVID-19 vaccine in record time."

    Dr. Afeyan continued, "In the last year alone, breakthroughs at Rubius Therapeutics, Denali Therapeutics, Seres Therapeutics, and others demonstrated the exponential impact bioplatforms can have on health. Biotechnology is at the leading edge of technological progress, challenging us to think beyond incremental advances and take big leaps – and Flagship Pioneering is focused on actively leaping to the scientific spaces ripe for disruption."

    Financial Update

    After Fund VII's close, Flagship is now operating with an aggregate capital pool of $6.7 billion, with $14.1 billion assets under management. Over the past four quarters, Flagship deployed $370 million in capital to its companies, combined with more than $4.4 billion from other capital providers, for a total of $4.8 billion in new capital fueling Flagship companies.

    "We are grateful to our longstanding Limited Partners and our new investors for their support as we pioneer life science solutions to tackle the world's most urgent issues," said Stephen Berenson, Managing Partner, Flagship Pioneering. "This expanded capital pool will enable us to support first-in-category platform companies, spanning human therapeutics, agriculture, and nutrition, as well as our soon-to-be-launched Preemptive Medicine and Health Security Initiative, and the development of a robust pipeline of clinical assets through our Pioneering Medicines Division."

    Driving Ground-breaking Multi-Product Bioplatforms                                      

    Flagship Pioneering is dedicated to exploring and innovating in uncharted spaces, as well as founding, launching, and advancing new companies to develop and commercialize these innovations.

    "The biological century is an era of new possibility. Today, the opportunity to harness biology for the benefit of humanity and the world is unprecedented," said Doug Cole, M.D., Managing Partner, Flagship Pioneering. "At Flagship, we challenge ourselves daily to discover what is not yet visible, invent what has previously not been possible, and imagine and realize new ways to treat, cure, diagnose, and prevent diseases."

    Flagship's team of entrepreneurial scientists, executives, and operations experts, as well as its companies, achieved important milestones in the last year, as follows:

    • Unveiled Generate Biomedicines, Invaio Sciences, Inzen Therapeutics, Laronde, and Valo Health
    • Raised $1.8 billion in private investments for early growth-stage companies: Cellarity, Inari Agriculture, Indigo Ag, Invaio Sciences, Omega Therapeutics, Repertoire Immune Medicines, Ring Therapeutics, Senda Biosciences, Tessera Therapeutics, and Valo Health
    • Completed Initial Public Offerings at Codiak Biosciences (NASDAQ:CDAK), Foghorn Therapeutics (NASDAQ:FHTX), Sana Biotechnology (NASDAQ:SANA), and Sigilon Therapeutics (NASDAQ:SGTX)
    • Raised follow-on public market capital in Axcella (NASDAQ:AXLA), Codiak Biosciences (NASDAQ:CDAK), Evelo (NASDAQ:EVLO), Kaleido (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius (NASDAQ:RUBY), and Seres (NASDAQ:MCRB)
    • Conducted more than 60 new explorations, the first step of our company origination process
    • Filed more than 300 patent applications from Flagship Labs
    • Flagship ecosystem companies have 53 clinical programs and 150 pre-clinical programs currently underway

    Assembling a World-Class Team

    Flagship is committed to bringing on the highest caliber industry executives with track records of exceptional performance, as evidenced in the company's new hires over the past year. These have included the recent additions of Christopher P. Austin, M.D., as CEO-Partner, Ara Darzi, M.D., as Chair, Preemptive Medicine and Health Security Initiative, Michael T. Nally, as CEO-Partner and CEO of Generate Biomedicines, and Louisa Salter-Cid, Ph.D., as Chief Scientific Officer for Pioneering Medicines. In addition, Flagship has hired a number of world class executives, scientists, and operations leaders to roles across the company and its ecosystem of companies. 

    Introducing Preemptive Medicine and Health Security, a New, More Comprehensive Approach to Health Security

    Flagship is actively building a division tasked with pioneering a new field that aims to protect, maintain, or improve people's health before they get sick by proactively intervening in those who are seemingly healthy but at risk. It will encompass interventions that protect health from external threats (health security) as well as to prevent or delay the onset of disease (preemptive health) to better prepare for the next infectious disease threats, and to pursue bolder treatments for existing pandemic diseases such as obesity, cancer, and neurodegeneration. Learn more about Flagship's perspective in this recent whitepaper, "Health Security and Beyond: A New Paradigm for a Post-Pandemic World."

    "The pandemic has laid bare the critical nature of health, not only to individuals, but to economies and societies," said Ara Darzi, M.D., Chair of Flagship's Preemptive Medicine and Health Security Initiative. "Flagship is pioneering a new field that aims to protect, maintain, and improve people's health by providing security against threats for everyone, and preventing or postponing the onset of disease for 'seemingly healthy' people, before they experience any recognisable symptoms at all."

    Building the Pioneering Medicines Division

    Flagship launched its Pioneering Medicines Division earlier this year to harness the power of Flagship's scientific and development innovation to create and advance novel therapeutic medicines that benefit more patients sooner. Given the broad applicability of many Flagship platforms, Pioneering Medicines is focused on expanding the reach of these scientific innovations by creating medicines in disease areas where the companies are not yet focused and working across platforms in unprecedented ways.

    "Pioneering Medicines is focused on innovative approaches to achieving greater impact for patients at faster speeds," said Paul Biondi, Executive Partner, Flagship Pioneering and President of Pioneering Medicines. "We are leveraging the innovative scientific platforms and technologies within Flagship Pioneering's ecosystem of companies to conceive and develop a unique portfolio of life-changing treatments for patients."

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ:DNLI), Indigo Ag, Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Valo Health.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flagship-pioneering-closes-3-4-billion-capital-pool-to-drive-continued-breakthrough-innovations-in-human-health-and-sustainability-301311419.html

    SOURCE Flagship Pioneering

    View Full Article Hide Full Article
View All Codiak BioSciences Inc. News